News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
HENLIUS (02696.HK) HLX43 for Injection Approved in Japan to Conduct Relevant Clinical Trials
HENLIUS (02696.HK) announced that the clinical trial notification recently submitted to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for HLX43 for injection, as monoth...
Reset
Send
The window will close in 5 seconds
HENLIUS (02696.HK) HLX43 for Injection Approved in Japan to Conduct Relevant Clinical Trials
Close
Recommend
2
Positive
0
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

HENLIUS (02696.HK)  -1.650 (-2.391%)    Short selling $2.09M; Ratio 6.948%   announced that the clinical trial notification recently submitted to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for HLX43 for injection, as monotherapy or in combination with pimurutamab HLX07, versus docetaxel for the treatment of advanced squamous non-small cell lung cancer (NSCLC) in an international multi-center Phase 2/3 clinical study, has received tacit approval. In accordance with relevant regulations, the clinical trial can be conducted in Japan. The company plans to initiate the relevant clinical research in Japan once conditions are met. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-14 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.